Personalis Stock Price, News & Analysis

Personalis, Inc. (NASDAQ: PSNL) will release its second quarter 2022 financial results on August 3, 2022. The company will also host a conference call and webcast at 2:00 p.m. PT to discuss financial outcomes and recent developments. Interested participants can register for the call via the provided link and access the live webinar on the company's website. Personalis is recognized for its advancements in cancer genomics, playing a pivotal role in precision oncology through the Personalis NeXT Platform®.

Personalis, Inc. (NASDAQ: PSNL) has added a new patent to its molecular residual disease (MRD) IP portfolio, issued on January 2013, focusing on tumor detection through whole genome sequencing. The newly granted US Patent No. 11,384,394 enhances the NeXT Personal™ platform, allowing for highly sensitive measurement of tumor burden. This patent strengthens Personalis' position in advanced genomic analysis with 21 issued patents and over 30 pending applications related to cancer detection and genomic sequencing. The approach could lead to earlier detection of cancer recurrence and improved treatment options.

Personalis, Inc. (Nasdaq: PSNL) reported Q1 2022 financial results with revenue of $15.2 million, down from $20.9 million in Q1 2021. Revenue from biopharma customers increased by 53% to $11.7 million, including $4.1 million from Natera. Revenue from the VA MVP dropped to $3.5 million from $13.2 million in the prior year. The company expects full-year 2022 revenue between $62.0 million and $67.0 million, with a projected net loss of $110.0 million to $115.0 million.

Personalis, Inc. (Nasdaq: PSNL) announced its participation in upcoming investor conferences to showcase its advancements in cancer genomics. The company will present at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 6:20 p.m. ET in Las Vegas, and at the UBS Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET in New York. Personalis is committed to enhancing precision cancer therapies through its innovative NeXT Platform, which evaluates nearly 20,000 human genes from a single sample.

Evaxion Biotech and Personalis announced a collaboration utilizing the ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy of Evaxion's cancer immunotherapy EVX-01. The trial will study the combination of EVX-01 with KEYTRUDA in metastatic melanoma patients. Evaxion's AI tool PIONEER is expected to enhance treatment precision by targeting significant cancer mutations. The partnership aims to improve patient outcomes and advance companion diagnostics. Both companies leverage advanced AI and genomic technologies to boost cancer therapy development.

Personalis, Inc. (Nasdaq: PSNL) announced the appointment of James Azzaro as the Vice President of Diagnostic Sales, a new role aimed at enhancing the company's clinical market presence. With over 20 years in oncology diagnostics, Azzaro is set to lead efforts to grow clinical test volumes and secure reimbursement for the NeXT Dx™ and NeXT Personal™ tests. CEO John West expressed confidence in Azzaro's ability to drive commercial success in partnering with healthcare systems and oncologists across the United States.

Personalis, Inc. (NASDAQ: PSNL) will release its Q1 2022 financial results on May 4, 2022, at 2:00 p.m. PT. Following the release, a conference call will occur to discuss financial results and highlights. Interested participants can join via phone or through a live webcast on the company's website.

Personalis specializes in advanced genomics for cancer treatments, utilizing the Personalis NeXT Platform to provide comprehensive genetic insights from single samples, enhancing precision cancer therapies.

Personalis, Inc. (NASDAQ: PSNL) has published a study in Nature Communications detailing the development of DASH, a machine learning-based algorithm for detecting human leukocyte antigen loss of heterozygosity (HLA LOH). This biomarker is crucial for cancer immunotherapy and helps cancer cells evade immune detection. The study showed DASH's increased sensitivity in identifying HLA LOH across various tumor types among 610 patients, with notable prevalence in non-small cell lung cancer (24%), cervical cancer (38%), and head and neck cancers (40%).

Personalis, Inc. (NASDAQ: PSNL) announced the issuance of US Patent No. 11,299,783 on April 12, 2022, concerning its NeXT Personal minimal residual disease (MRD) detection platform. This patent covers innovative methods for a personalized assay, enhancing tumor burden measurement and tracking of tumor variants. The NeXT Personal platform uniquely integrates detection and characterization of tumors, positioning it as a potential new standard in cancer monitoring. Personalis now holds 19 patents in genomic sequencing and analysis, with over 25 additional applications pending.